Expansion of North American sales and the impact of new customers and new products
First written in FY2016. 24 of 32 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
Japan Medical Dynamic Marketing moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2026: 2 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Other".
- FY2026U.S. external-customer revenue declined for the full yearAnnual report
「Sales to external customers in the United States decreased by US$3,699 thousand, or 4.9%, year on year, to US$71,579 thousand. In yen terms, sales decreased by ¥672 million, or 5.9%, to ¥10,807 million, due to the impact of the stronger yen.」
Sales to external customers in the United States declined in both U.S. dollar terms and after translation into yen, reversing the revenue growth generated by customer base expansion through the previous fiscal year. - 2026-05-08WorsenedEarnings
「Sales in the U.S. artificial joint market were US$71,363 thousand, down 4.9% from the previous fiscal year, or ¥10,774 million in yen terms, down 5.9% due in part to the impact of the stronger yen.」
Although the nationwide rollout of the new product progressed, the U.S. artificial joint market as a whole recorded lower sales. - FY2026-H1Sales to external customers in the United States declined in both U.S. dollar and yen termsAnnual report
「Sales to external customers in the U.S. decreased by US$145 thousand, or 0.4%, year on year to US$35,802 thousand. After translation into yen, sales decreased by ¥228 million, or 4.2%, year on year to ¥5,247 million, reflecting the stronger yen.」
Although the new customer base and new products made progress, sales to external customers in the United States declined 0.4% in U.S. dollar terms and 4.2% after translation into yen. - FY2025-H1AdvancedAnnual report
「Sales to external customers in the United States increased by 1,815 thousand US dollars, or 5.3% year on year, to 35,947 thousand US dollars. After translation into yen, sales increased by ¥653 million, or 13.5% year on year, due to yen depreciation, to ¥5,476 million.」
Sales to external customers in the United States rose 5.3% year on year in U.S. dollar terms and 13.5% after translation into yen. The disclosure also noted an increase in TKA procedures as the customer base expanded and the launch of new product sales. - FY2024AdvancedAnnual report
「In the U.S. artificial joint segment, the number of acquired total knee arthroplasty (TKA) procedures involving artificial knee products such as BKS TriMax and BKS Revision Knee increased as the customer base expanded, and sales performed strongly with double-digit growth.」
In the United States, the number of artificial knee procedures and sales increased as the customer base expanded, and the North American business continued to grow. However, the disclosure also noted sales declines for certain artificial hip products due to customers switching to competitors. - FY2024-Q3AdvancedAnnual report
「In the United States, new customers developed the previous year contributed to growth, and the number of cases acquired for total knee arthroplasty products increased. As a result, sales to external customers in the United States rose to US$52.205 million, up US$3.138 million, or 6.4%, year on year, and to ¥7,452 million after translation into yen, up ¥808 million, or 12.2%, due to the weaker yen.」
Growth in the new customer base and an increase in procedures involving artificial knee products drove sales to external customers in the United States up 6.4% in U.S. dollar terms and 12.2% after translation into yen. - FY2024-Q2AdvancedAnnual report
「In the United States, new customers developed the previous year contributed to growth, and the number of cases acquired for total knee arthroplasty products increased. As a result, sales to external customers in the United States rose to US$34 million, up US$2 million, or 8.9%, year on year, and to ¥4,823 million after translation into yen, up ¥638 million, or 15.3%, due to the weaker yen.」
Growth in the new customer base and an increase in procedures involving artificial knee products drove sales to external customers in the United States up 8.9% in U.S. dollar terms and 15.3% after translation into yen. - FY2024-Q1AdvancedAnnual report
「In the United States, new customers developed the previous year contributed to growth, and the number of cases acquired for total knee arthroplasty products increased. As a result, sales to external customers in the United States rose to US$16 million, up US$0.7 million, or 4.8%, year on year, and to ¥2,347 million after translation into yen, up ¥253 million, or 12.1%, due to the weaker yen.」
Growth in the new customer base and an increase in procedures involving artificial knee products drove sales to external customers in the United States up 4.8% in U.S. dollar terms and 12.1% after translation into yen. - FY2023-Q3AdvancedAnnual report
「In the United States, the supply chain issues that arose in the first half showed signs of improvement compared with the same quarter of the previous year. The Group gradually resumed supplying products to new customers whose supply had been suspended and expanded its customer base, while increasing the number of cases secured through various sales expansion initiatives for existing customers. As a result, sales to external customers in the United States increased 4.3% year on year in U.S. dollar terms and, after translation into yen, increased 26.8% to ¥6,644 million due to the weaker yen.」
Expansion of the customer base and the number of procedures acquired, driven by sales to new customers following the resumption of supply and initiatives to expand sales to existing customers, led sales to external customers in the United States to rise 4.3% in U.S. dollar terms. - FY2023-Q2AdvancedAnnual report
「In the United States, the number of cases acquired increased year on year due to the contribution of the customer base, which had continued to expand from the previous year. As a result, sales to external customers increased 1.9% year on year in U.S. dollar terms and 23.3% after translation into yen due to the weaker yen, to ¥4,184 million.」
Sales to external customers in the United States rose 1.9% year on year in U.S. dollar terms and 23.3% after translation into yen, which was affected by yen depreciation. U.S. dollar-denominated sales turned upward from a decline in the previous quarter. - FY2023-Q1U.S. dollar-denominated sales declined, while sales after translation into yen increased due to yen depreciationAnnual report
「In the United States, case volumes increased compared with the same quarter of the previous year, when case volumes had increased as sales activities recovered with the expansion of COVID-19 vaccinations. However, due in part to the decline in revenue per case, sales to external customers declined 1.6% year on year in U.S. dollar terms, while increased 15.4% after translation into yen due to the weaker yen, to ¥2,093 million.」
Sales to external customers in the United States declined 1.6% year on year in U.S. dollar terms, but increased 15.4% after translation into yen due to yen depreciation. - FY2022-Q3AdvancedAnnual report
「In the artificial joint products field, sales of artificial knee products and other products in the United States recovered, and combined revenue in Japan and the United States increased 15.4% year on year, comprising increases of 4.5% in Japan and 23.9% in the United States, to ¥8,615 million. In the osteosynthesis products field, domestic revenue in Japan increased 10.6% year on year to ¥2,926 million, as ASULOCK and Prima Hip Screw sales continued to perform steadily. In the spinal fixation products field, combined revenue in Japan and the United States increased 21.0% year on year to ¥2,322 million, as KMC Kyphoplasty System sales in Japan continued to perform well.」
Sales in the artificial joint, osteosynthesis materials and spinal fixation devices segments exceeded the same period of the previous year, with sales growth indicated for artificial joints in the United States, ASULOCK, Prima Hip Screw and the KMC Kyphoplasty System. - FY2022-Q2AdvancedAnnual report
「Meanwhile, sales to external customers in the United States recovered, rising 22.3% year on year in U.S. dollars and 26.3% after translation into yen to ¥3,392 million. However, from the second quarter onward, U.S. sales did not reach the level of the same quarter two years earlier, before the COVID-19 pandemic, because scheduled surgeries were postponed again as infections resurged in the United States.」
Although sales to external customers in the United States recovered year on year, they did not reach pre-pandemic levels because surgeries were postponed as infections resurged. - FY2022-Q1AdvancedAnnual report
「As the group's operating activities in the United States were returning to normal, sales to external customers in the United States rose 76.2% year on year in U.S. dollars and 79.9% after translation into yen to ¥1,814 million, recovering to the level of the same quarter two years earlier, before the COVID-19 pandemic.」
Sales to external customers in the United States increased substantially year on year, recovering to pre-pandemic levels. - FY2021-Q3Continued decline in U.S. sales due to COVID-19Annual report
「However, the United States was significantly affected by COVID-19, and sales to external customers declined 20.1% year on year in U.S. dollar terms and 22.4% after translation into yen to ¥4,226 million.」
Sales to external customers in the United States declined 20.1% in U.S. dollar terms and 22.4% after translation into yen, with COVID-19-related revenue declines continuing. - FY2021-Q2U.S. sales declined due to COVID-19Annual report
「Sales declined as the number of procedures fell due to the impact of COVID-19 in Japan and the United States. Sales in Japan declined 3.5% year on year to ¥5,067 million, while sales to external customers in the United States fell 22.3% year on year in U.S. dollar terms and 24.0% after translation into yen to ¥2,685 million.」
Sales to external customers in the United States declined 22.3% in U.S. dollar terms and 24.0% after translation into yen due to the decline in procedure volumes caused by COVID-19. - FY2021-Q1U.S. sales plunged due to COVID-19Annual report
「Sales declined as the number of procedures fell due to the impact of COVID-19 in Japan and the United States. Sales in Japan declined 8.0% year on year to ¥2,400 million, while sales to external customers in the United States fell 41.3% year on year in U.S. dollar terms and 42.5% after translation into yen to ¥1,008 million.」
Sales to external customers in North America declined 41.3% in U.S. dollar terms and 42.5% after translation into yen due to the decline in procedure volumes caused by COVID-19. - FY2020AdvancedAnnual report
「Although the United States was significantly affected by numerous procedure postponements and cancellations due to COVID-19 from mid-March, cumulative sales in the artificial joint segment remained solid. Sales to external customers rose 10.6% year on year in U.S. dollar terms and 9.1% after translation into yen to ¥7,161 million.」
In the United States, sales to external customers, centered on artificial joints, rose 10.6% in U.S. dollar terms and 9.1% after translation into yen, despite the impact of COVID-19-related procedure postponements and cancellations. - FY2020-Q3AdvancedAnnual report
「In the artificial joint segment, sales of the BKS TriMaxPS artificial knee product and the new Entrada Hip Stem artificial hip product, launched progressively from September 2019 in Japan, remained solid. Sales of the new BKS Revision Tibial Cones and BKS Revision Sleeves artificial knee products also remained solid in the United States. As a result, combined sales in Japan and the United States rose 11.4% year on year to ¥8,719 million (up 5.2% in Japan and 15.6% in the United States). In the osteosynthesis materials segment, sales of the OM Femoral Nail System III (product name: ASULOCK) remained solid despite inventory shortages, driving sales in Japan up 10.2% year on year to ¥2,828 million. In the spinal fixation devices segment, sales of the KMC Kyphoplasty System remained solid in Japan, driving combined sales in Japan and the United States up 17.3% year on year to ¥1,650 million (up 18.6% in Japan and down 35.7% in the United States).」
Sales growth was indicated in the artificial joint, osteosynthesis materials and spinal fixation devices segments. Combined artificial joint sales in Japan and the United States rose 11.4%, domestic osteosynthesis materials sales increased 10.2%, and combined spinal fixation device sales in Japan and the United States rose 17.3%, while U.S. spinal fixation device sales declined 35.7%. - FY2020-Q2AdvancedAnnual report
「In the artificial joint segment, sales of the OVATION HIP System artificial hip product and BKS TriMaxPS artificial knee product remained solid in Japan, while sales of the new BKS Revision Tibial Cones and BKS Revision Sleeves artificial knee products also remained solid in the United States. As a result, combined sales in Japan and the United States rose 14.5% year on year to ¥5,683 million (up 7.4% in Japan and 19.3% in the United States). In the osteosynthesis materials segment, solid sales of the OM Femoral Nail System III (product name: ASULOCK) drove sales in Japan up 15.0% year on year to ¥1,767 million. In the spinal fixation devices segment, sales of the KMC Kyphoplasty System remained solid in Japan, driving combined sales in Japan and the United States up 26.1% year on year to ¥1,127 million (up 26.8% in Japan and down 7.7% in the United States).」
Specific product sales growth was indicated in the artificial joint, osteosynthesis materials and spinal fixation devices segments. Combined artificial joint sales in Japan and the United States rose 14.5%, domestic osteosynthesis materials sales increased 15.0%, and combined spinal fixation device sales in Japan and the United States rose 26.1%, while U.S. spinal fixation device sales declined 7.7%. - FY2020-Q1AdvancedAnnual report
「Sales in the artificial joint segment remained solid in the United States, with sales to external customers rising 19.2% year on year in U.S. dollar terms and 20.6% after translation into yen to ¥1,755 million.」
Sales to external customers in the United States rose 19.2% year on year in U.S. dollar terms and 20.6% after translation into yen. - FY2019-Q3AdvancedAnnual report
「In the artificial joint segment, although sales of artificial hip products declined in Japan, solid sales of the Entrada Hip Stem artificial hip product and artificial knee products in the United States drove combined sales in Japan and the United States up 12.0% year on year to ¥7,824 million (down 3.6% in Japan and up 25.6% in the United States). In the osteosynthesis materials segment, sales of the new OM Femoral Nail System III (product name: ASULOCK) and the ARISTO Nail System remained solid, driving sales in Japan up 16.8% year on year to ¥2,566 million. In the spinal fixation devices segment, sales of the new KMC Kyphoplasty System and Resolve Halo System remained solid, driving combined sales in Japan and the United States up 11.7% year on year to ¥1,406 million (up 14.3% in Japan and down 43.3% in the United States).」
Combined sales of artificial joints in Japan and the United States rose 12.0%, domestic sales of osteosynthesis materials increased 16.8%, and combined sales of spinal fixation devices in Japan and the United States rose 11.7%. New products contributed to sales, while domestic artificial joint sales and U.S. spinal fixation device sales declined. - FY2019-Q2AdvancedAnnual report
「In the artificial joint segment, although sales of artificial hip products declined in Japan, solid sales of the Entrada Hip Stem artificial hip product and artificial knee products in the United States drove combined sales in Japan and the United States up 13.7% year on year to ¥4,963 million (down 2.5% in Japan and up 28.5% in the United States). In the osteosynthesis materials segment, sales of the ARISTO Nail System and OM Femoral Nail System III (product name: ASULOCK) remained solid, driving sales in Japan up 17.3% year on year to ¥1,536 million. In the spinal fixation devices segment, sales of the new KMC Kyphoplasty System and Resolve Halo System remained solid, driving combined sales in Japan and the United States up 9.9% year on year to ¥894 million (up 12.2% in Japan and down 44.8% in the United States).」
Combined sales in Japan and the United States in the artificial joint segment rose 13.7%, domestic sales of osteosynthesis materials increased 17.3%, and combined sales of spinal fixation devices in Japan and the United States rose 9.9%. While sales growth of new and individual products was indicated, U.S. sales of spinal fixation devices declined 44.8%. - FY2019-Q1AdvancedAnnual report
「In the artificial joint segment, although sales declined in Japan, solid sales of the Entrada Hip Stem artificial hip product and artificial knee products in the United States drove combined sales in Japan and the United States up 9.7% year on year to ¥2,488 million (down 3.8% in Japan and up 22.2% in the United States).」
Combined sales in Japan and the United States in the artificial joint segment rose 9.7% year on year, while U.S. sales increased 22.2%. In the United States, the Entrada Hip Stem and artificial knee products contributed, whereas sales in Japan declined 3.8%. - FY2018-Q3AdvancedAnnual report
「In artificial joints, sales in Japan of ODEV's Alpine Cemented Hip Stem and Ovation Hip System remained firm, as did sales in the U.S. of products including BKS TriMax. As a result, combined revenue in Japan and the U.S. increased 7.3% year on year to ¥6,984 million, with Japan up 0.5% and the U.S. up 13.9%.」
In artificial joints, the Alpine Cemented Hip Stem, Ovation Hip System and BKS TriMax contributed to a 7.3% year-on-year increase in combined revenue in Japan and the U.S., while U.S. revenue rose 13.9%. - FY2018-Q2AdvancedAnnual report
「In artificial joints, continued firm sales of ODEV's Alpine Cemented Hip Stem and Ovation Hip System resulted in combined revenue in Japan and the U.S. of ¥4,363 million, up 4.4% year on year, with Japan up 0.8% and the U.S. up 7.9%.」
In artificial joints, the Alpine Cemented Hip Stem and Ovation Hip System contributed to a 4.4% year-on-year increase in combined revenue in Japan and the U.S., while U.S. revenue rose 7.9%. - FY2018-Q1AdvancedAnnual report
「Sales of artificial joint products, including BKS TriMax, remained firm in the U.S. Revenue from external customers increased 6.4% year on year in U.S. dollar terms and 8.4% on a yen-converted basis to ¥1,195 million.」
In the U.S., artificial joint products, including BKS TriMax, remained firm. Revenue from external customers increased 6.4% in U.S. dollar terms and 8.4% on a yen-converted basis. - FY2017AdvancedAnnual report
「In artificial joints, continued firm sales of ODEV's Ovation Hip System resulted in combined revenue in Japan and the U.S. of ¥8,941 million, up 9.1% from the previous consolidated fiscal year, with Japan up 9.3% and the U.S. up 8.9%. In spinal fixation devices, combined revenue in Japan and the U.S. was ¥1,404 million, down 5.0%, with Japan up 1.4% and the U.S. down 46.6%.」
Artificial joint revenue in Japan and the U.S. combined increased 9.1%, while spinal fixation device revenue declined 5.0%, including a 46.6% decline in the U.S., showing differing full-year results by product category. - FY2017-Q3AdvancedAnnual report
「Sales of artificial joint products, including the Alpine Hip System, remained firm in the U.S. Revenue from external customers increased 18.2% year on year in U.S. dollar terms, but due to the appreciation of the yen, rose 5.2% on a yen-converted basis to ¥3,367 million. In artificial joints, continued firm sales of ODEV's Ovation Hip System resulted in combined revenue in Japan and the U.S. of ¥6,510 million, up 9.7% year on year, with Japan up 11.9% and the U.S. up 7.6%. In spinal fixation devices, combined revenue in Japan and the U.S. was ¥1,061 million, down 4.9% year on year, with Japan up 1.0% and the U.S. down 42.9%.」
North American revenue expanded, mainly driven by artificial joints, with the effects of new and existing products continuing. In spinal fixation devices, however, U.S. revenue declined 42.9% year on year, showing differing trends by product category. - FY2017-Q2AdvancedAnnual report
「Sales of artificial joint products, including the new Alpine Hip System, remained firm in the U.S. Revenue from external customers increased 15.5% year on year in U.S. dollar terms, but due to the appreciation of the yen, rose only 1.4% on a yen-converted basis to ¥2,179 million. In spinal fixation devices, sales of ODEV's IBIS Spinal System remained firm in Japan, but U.S. sales declined, resulting in combined revenue in Japan and the U.S. of ¥728 million, down 3.4% year on year, with Japan up 4.3% and the U.S. down 49.1%.」
In North America, artificial joint revenue increased in U.S. dollar terms, while U.S. revenue from spinal fixation devices declined 49.1% year on year, showing differing trends by product category. - FY2017-Q1AdvancedAnnual report
「In the United States, sales of orthopaedic joint products, including the new Alpine Hip System, remained firm, and sales to external customers increased to ¥1,102 million, up 4.3% year on year, or 15.5% in U.S. dollar terms.」
Sales of artificial joint products, including new products, remained firm in the U.S., increasing revenue from external customers. - FY2016First statedAnnual report
「Sales of artificial joint products remained firm in the U.S., and revenue from external customers increased 15.9% year on year, or 6.2% in U.S. dollar terms, to ¥4,291 million.」
External-customer revenue increased in North America, mainly driven by artificial joint products.